Previous 10 | Next 10 |
Several mergers have been announced over the past few days and this has driven cannabis stocks upwards. A newer industry is still seeing tremendous growth rates in QoQ revenues. Keeping an eye on the fastest growing revenue stocks may be key to increasing profits in investments. ...
LAS VEGAS, NV / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Mast-Cell-Associated or Basophil-M...
LAS VEGAS, NV / ACCESSWIRE / October 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of chr...
GB Sciences ( OTCQB:GBLX +7.3% ) has filed a provisional patent application, for the use of its new proprietary cannabinoid containing complex mixtures (CCCM) for the treatment of Cytokine Storm Syndromes (CSS), including acute respiratory distress syndrome in COVID-19 patients. More n...
LAS VEGAS, NV / ACCESSWIRE / August 26, 2020 / GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of Cytokine Sto...
GB Sciences ( OTCQB:GBLX +1.5% ) receives new U.S. patent (No. 10,709,670) covering the use of Myrcene-Containing Complex Mixtures (MCCM) for the treatment of pain disorders related to arthritis, shingles, irritable bowel syndrome, sickle cell disease, and endometriosis. More news...
LAS VEGAS, NV / ACCESSWIRE / July 20, 2020 / GB Sciences, Inc. (OTCQB:GBLX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,709,670 entitled "Myrcene-Containing Complex Mixtures Targeting TRPV1" on July 14, 2020. This US patent is as...
LAS VEGAS, NV / ACCESSWIRE / May 4, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced today that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,653,640 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Neurodegenerative Diseases" on Ma...
LAS VEGAS / ACCESSWIRE / April 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), is pleased to announce that the company's Canadian entity, GBS Global Biopharma, Inc. (GBS), signed an Amendment to their Agreement with the National Research Council of Canada (NRC). The NRC has demonstrated that the ...
Illinois is ringing in the new decade by becoming the 11th state in the country and the District of Columbia to allow the legal sale and purchase of marijuana. More news on: Aurora Cannabis Inc., Cronos Group Inc., Tilray, Inc., News on the U.S. economy, News on ETFs, Read more ...
News, Short Squeeze, Breakout and More Instantly...
LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infect...
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which...
LAS VEGAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selec...